First-Line Topical Combination Treatment for Mild to Moderate Psoriasis

For mild to moderate psoriasis, evidence-based guidelines support a first-line topical approach combining two classes of agents — a topical retinoid and a topical corticosteroid — rather than either therapy alone.

Clinical Scenario

Mild to moderate plaque psoriasis where topical therapy is the primary treatment strategy and combination treatment is indicated to improve outcomes over monotherapy.

Treatment Approach

The recommended first-line regimen involves a topical retinoid combined with a topical corticosteroid, and has been shown to be more effective than either agent used alone.

Full protocol details — including specific agents, potency selection, application frequency, and treatment duration — are available in the complete structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaad.2020.07.087

The use of mid- or high-potency topical corticosteroid in combination with tazarotene for 8-16 weeks is more effective than monotherapy with tazarotene and is recommended for the treatment of mild to moderate psoriasis.

View source ↗